Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 12;17(1):163.
doi: 10.1186/s13023-022-02299-5.

The national economic burden of rare disease in the United States in 2019

Grace Yang  1 , Inna Cintina  1 , Anne Pariser  2 , Elisabeth Oehrlein  3 , Jamie Sullivan  4 , Annie Kennedy  5
Affiliations

The national economic burden of rare disease in the United States in 2019

Grace Yang et al. Orphanet J Rare Dis. .

Abstract

Background: To provide a comprehensive assessment of the total economic burden of rare diseases (RD) in the United States (U.S.) in 2019. We followed a prevalence-based approach that combined the prevalence of 379 RDs with the per-person direct medical and indirect costs, to derive the national economic burden by patient age and type of RD. To estimate the prevalence and the direct medical cost of RD, we used claims data from three sources: Medicare 5% Standard Analytical File, Transformed Medicaid Statistical Information System, and Optum claims data for the privately insured. To estimate indirect and non-medical cost components, we worked with the rare disease community to design and implement a primary survey.

Results: There were an estimated 15.5 million U.S. children (N = 1,322,886) and adults (N = 14,222,299) with any of the 379 RDs in 2019 with a total economic burden of $997 billion, including a direct medical cost of $449 billion (45%), $437 billion (44%) in indirect costs, $73 billion in non-medical costs (7%), and $38 billion (4%) in healthcare costs not covered by insurance. The top drivers for excess medical costs associated with RD are hospital inpatient care and prescription medication; the top indirect cost categories are labor market productivity losses due to absenteeism, presenteeism, and early retirement.

Conclusions: Our findings highlight the scale of the RD economic burden and call for immediate attention from the scientific communities, policy leaders, and other key stakeholders such as health care providers and employers, to think innovatively and collectively, to identify new ways to help improve the care, management, and treatment of these often-devastating diseases.

Keywords: Direct cost; Economic burden; Indirect cost; Rare disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Total Economic Burden of Rare Disease in the U.S. in 2019: $997 Billion
Fig. 2
Fig. 2
Data sources for the economic burden estimates
See this image and copyright information in PMC

References

    1. Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–78. doi: 10.1038/d41573-019-00180-y. - DOI - PMC - PubMed
    1. National Human Genome Research Institute. Rare diseases FAQ. January 10, 2020. https://www.genome.gov/FAQ/Rare-Diseases. Accessed 19 Apr 2021.
    1. Forshaw R. What is the cost of living with rare disease? https://raremark.com/articles/what-does-it-cost-to-live-with-a-rare-dise.... Accessed 29 Jan 2021.
    1. Therapies, Shire Human Genetic. Rare disease impact report: insights from patients and the medical community. Shire Human Genetic Therapies, Tech. Rep; 2013.
    1. Mighiu C, O'Hara S, Ferri Grazzi E, Murray KF, Schattenberg JM, Ventura E, Karakaidos M, Taylor A, Brrang H, Dhawan A, Willemse J, Finnegan A. Impact of progressive familial intrahepatic cholestasis on caregivers: caregiver-reported outcomes from the multinational PICTURE study. Orphanet J Rare Dis. 2022;17(1):32. doi: 10.1186/s13023-022-02177-0. - DOI - PMC - PubMed

Publication types